Ensuring safe drug administration to pediatric patients with renal dysfunction: a multicenter study

Ryoko Harada(Tokyo Metropolitan Children's Medical Center), Masataka Honda(Rikkyo University), Kazumoto Iijima(Kobe Children's Hospital), Yoshihiko Morikawa(Tokyo Metropolitan Children's Medical Center), Hirotaka Takahashi(Tokyo Metropolitan Ohtsuka Hospital), Tae Omori(Inserm), Riku Hamada, Shunsuke Shinozuka(National Hospital Organization), Naoaki Mikami(Tokyo Metropolitan Children's Medical Center), Hiroshi Hataya(Japanese Society for Dialysis Therapy), Kenji Ishikura(Kitasato University), Tetsuji Kaneko(Teikyo University of Science), Yuko Hamasaki(Toho University)
Clinical and Experimental Nephrology
February 6, 2018
10.1007/s10157-018-1537-7
Cited by 3

Related Papers

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial
|The Lancet|2014|450
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|278
Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease
|Clinical and Experimental Nephrology|2013|267
High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD)
|Circulation|2018|242
Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies
|Pediatric Nephrology|2021|149